FIELD: medicine, pharmaceutics.
SUBSTANCE: what is described is a specific combination - [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3'-methyl-2'-(valeroyl{2"-(tetrazol-5-ylate)biphenyl-4'-ylmethyl}amino)butyrate] trisodium salt pentahydrate in a solid state which is a double-action compound of angiotensin receptor antagonist and NEP inhibitor, a method for preparing it, a pharmaceutical composition and using said combination for hypertension and cardiac failure.
EFFECT: preparing the combination for hypertension and cardiac failure.
16 cl, 5 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMBINATIONS OF ANGIOTENSIN RECEPTOR ANTAGONIST AND NEP INHIBITOR | 2006 |
|
RU2503668C2 |
| DOUBLE-ACTION PHARMACEUTICAL COMPOSITIONS OF SUBMOLECULAR STRUCTURE OF ANGIOTENSIN RECEPTOR BLOCKER (ARB) AND NEUTRAL ENDOPEPTIDASE (NEP) INHIBITOR | 2008 |
|
RU2493844C2 |
| NEP INHIBITORS FOR TREATMENT OF DISEASES CHARACTERIZED BY ATRIAL ENLARGEMENT OR REMODELING | 2018 |
|
RU2809222C2 |
| NEP INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ATRIAL ENLARGEMENT OR REMODELING | 2013 |
|
RU2667643C2 |
| GALENIC COMPOSITIONS OF ORGANIC COMPOUNDS | 2017 |
|
RU2773029C2 |
| SALTS OF 2'-(1H-TETRAZOL-5-YL)-1 AND 1'-BIPHENYL-4-CARBOXALDEHYDE WITH METALS | 2006 |
|
RU2435761C2 |
| VALSARTAN SALTS, PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHOD FOR PREPARING SALTS | 2001 |
|
RU2275363C2 |
| APPLICATION OF VALSARTAN OR METABOLITE THEREOF FOR INHIBITION OF THROMBOCYTE AGGREGATION | 2003 |
|
RU2334512C2 |
| TREATMENT OF HYPERTENSION AND/OR PREVENTION AND TREATMENT OF HEART FAILURE IN MAMMAL, RECEIVING ANTICOAGULANT THERAPY | 2011 |
|
RU2564941C2 |
| SUBSTITUTED DERIVATIVES OF BISPHENYL ESTER OF BUTYRIC ACID AS NEP INHIBITORS | 2019 |
|
RU2784522C2 |
